Do you send Oncotype in patients with ER/PR+ breast cancer and micrometastasis in one sentinel node?

I do send a Mammaprint, as the MINDACT trial (NEJM 2016) demonstrated that women with ER positive breast cancer and 0-3 LN with a low risk profile had a 94.5% 5 year distant disease free survival with endocrine therapy alone. If high risk, I'd offer AC x 4, taxol x 12, which is my standard regimen f...

21 gene Recurrence score would be my preference. Unless there is a surprise, a patient with a strongly ER/PR positive, grade 2 tumor is most likely to have low risk disease and endocrine therapy alone is enough. Would be good to hear an update on whether further testing was done and in what risk ran...